-
Key approvals see big sales in first months
Among the 22 novel new drugs approved by the Food and Drug Administration in 2016, about half were considered specialty drugs, and Diplomat identified four key specialty approvals that innovate in certain categories. Two of these were in the hepatitis C space, which has driven specialty growth for several years.
(To view the full Category Review, click here.)
-
Aromatherapy makes plenty of ‘scents’ for retailers
For those retailers bold enough to sniff out a fresh opportunity, at least as far as the mass merchant space is concerned, aromatherapy realized some rosy sales gains in 2016. Citing Nielsen data, Piping Rock reported the aromatherapy opportunity in mass is racing along at an annual growth trajectory of 121%, reaching $44 million for the 52 weeks ended Dec. 31, 2016 across all outlets combined.
(To view the full Category Review, click here.)